Tags

Type your tag names separated by a space and hit enter

Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis.
J Clin Med. 2020 Apr 24; 9(4)JC

Abstract

Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation.

Authors+Show Affiliations

Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria.Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria.Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria.Institute of Medical Statistics, Medical University Vienna, 1090 Vienna, Austria.Institute of Medical Statistics, Medical University Vienna, 1090 Vienna, Austria.Department of Dermatology, Rudolfstiftung City Hospital, 1030 Vienna, Austria.Department of Dermatology, Kepler University Hospital, 4020 Linz, Austria. Department of Soft Matter Physics, Institute for Experimental Physics, Johannes Kepler University, 4020 Linz, Austria.Department of Dermatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Dermatology, Rudolfstiftung City Hospital, 1030 Vienna, Austria.Department of Dermatology, Wiener Neustadt Public Hospital, 2700 Wiener Neustadt, Austria.Department of Dermatology, Kepler University Hospital, 4020 Linz, Austria.Department of Dermatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32344789

Citation

Quint, Tamara, et al. "Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis." Journal of Clinical Medicine, vol. 9, no. 4, 2020.
Quint T, Brunner PM, Sinz C, et al. Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. J Clin Med. 2020;9(4).
Quint, T., Brunner, P. M., Sinz, C., Steiner, I., Ristl, R., Vigl, K., Kimeswenger, S., Neubauer, K., Pirkhammer, D., Zikeli, M., Hoetzenecker, W., Reider, N., & Bangert, C. (2020). Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. Journal of Clinical Medicine, 9(4). https://doi.org/10.3390/jcm9041241
Quint T, et al. Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. J Clin Med. 2020 Apr 24;9(4) PubMed PMID: 32344789.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. AU - Quint,Tamara, AU - Brunner,Patrick M, AU - Sinz,Christoph, AU - Steiner,Irene, AU - Ristl,Robin, AU - Vigl,Kornelia, AU - Kimeswenger,Susanne, AU - Neubauer,Katharina, AU - Pirkhammer,Detlev, AU - Zikeli,Martin, AU - Hoetzenecker,Wolfram, AU - Reider,Norbert, AU - Bangert,Christine, Y1 - 2020/04/24/ PY - 2020/04/09/received PY - 2020/04/18/revised PY - 2020/04/22/accepted PY - 2020/4/30/entrez PY - 2020/4/30/pubmed PY - 2020/4/30/medline KW - Dupilumab KW - atopic dermatitis KW - biologicals KW - conjunctivitis KW - rosacea-like folliculitis JF - Journal of clinical medicine JO - J Clin Med VL - 9 IS - 4 N2 - Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation. SN - 2077-0383 UR - https://www.unboundmedicine.com/medline/citation/32344789/Dupilumab_for_the_Treatment_of_Atopic_Dermatitis_in_an_Austrian_Cohort-Real-Life_Data_Shows_Rosacea-Like_Folliculitis L2 - https://www.mdpi.com/resolver?pii=jcm9041241 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.